中国批准CMS-D008, 一种新SiRNA药物, 用于针对肝脏基因INHBE的肥胖试验。 China approves CMS-D008, a new siRNA drug, for obesity trials targeting liver gene INHBE.

中国医疗系统控股有限公司(CMS)于2026年3月4日宣布, 其针对肝脏内INHBE基因的SiRNA药物CMS-D008获得中国NMPA批准, 开始治疗超重和肥胖症临床试验。 China Medical System Holdings Limited (CMS) announced on March 4, 2026, that its siRNA drug CMS-D008, targeting the INHBE gene in the liver, received approval from China’s NMPA to begin clinical trials for treating overweight and obesity. 该药物通过亚皮注射施用,目的是通过抑制E-ALK7活性信号,减少脂肪积累,同时保持肌肉质量,这一机制不同于目前的GLP-1受体激动剂。 The drug, administered via subcutaneous injection, aims to reduce fat accumulation while preserving muscle mass by inhibiting Activin E-ALK7 signaling, a mechanism distinct from current GLP-1 receptor agonists. 目前正在为具有相关代谢条件的超重、肥胖和腹部肥胖患者开发该药物。 It is being developed for overweight, obese, and abdominal obesity patients with related metabolic conditions. CMS计划将CMS-D008与调查性的双重激动剂CMS-D005结合起来,以提高体重损失和长期维护。 CMS plans to combine CMS-D008 with its investigational dual agonist CMS-D005 to enhance weight loss and long-term maintenance. 该公司正在利用其在心血管和代谢疾病方面已建立的研发、制造和商业化基础设施推进试验。 The company is advancing trials using its established R&D, manufacturing, and commercialization infrastructure in cardiovascular and metabolic diseases.